Loading
The selective RET inhibitor selpercatinib cut the risk of progression by more than 70 percent compared with the older multikinase drugs cabozantinib and vandetanib in RET-mutant medullary thyroid cancer, with fewer side effects.
Phase 3 trial of 291 patients with progressive advanced RET-mutant medullary thyroid cancer randomised 2:1 to selpercatinib or physician's choice of cabozantinib or vandetanib.
Progression-free survival at 12 months was 86.8 versus 65.7 percent (hazard ratio 0.28), response 69.4 versus 38.8 percent, and treatment-failure-free survival also favoured selpercatinib; grade 3 or higher adverse events were 52.8 versus 76.3 percent.
Selpercatinib is the first-line standard for advanced RET-mutant medullary thyroid cancer; RET testing at diagnosis is essential.
Shares Medullary thyroid cancer, Selpercatinib.
Shares LIBRETTO-531, Selpercatinib.
Shares LIBRETTO-531, Medullary thyroid cancer, Selpercatinib.
Shares LIBRETTO-531, Selpercatinib.
Shares LIBRETTO-531, Medullary thyroid cancer.
Shares Medullary thyroid cancer, Selpercatinib.